SCHEMBL13149262

SCHEMBL13149262

Nc1cnccc1-c1ccccc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
GPBAR1 Q8TDU6 4/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
PIM1 P11309 4/20 0.42
PIM3 Q86V86 4/20 0.42
PIM2 Q9P1W9 4/20 0.42
F10 P00742 1/20 0.41
F7 P08709 1/20 0.41
F3 P13726 1/20 0.41
MPL P40238 1/20 0.41
NUDT1 P36639 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29939393 1.00 ALDH1A1 (0.46) ALDH1A1KDM4EGPBAR1GLAGAA
SCHEMBL21857846 0.85 ALDH1A1 (0.50) ALDH1A1GPBAR1MAOAMAOBNUDT1
SCHEMBL17506374 0.81 AOC1 (0.52) ALDH1A1KDM4EGLAGAASMN1; SMN2
SCHEMBL12303734 0.78 ALDH1A1 (0.45) ALDH1A1GPBAR1PIM1NUDT1RPS6KA3
SCHEMBL30445313 0.78 GPBAR1 (0.42) ALDH1A1GPBAR1NUDT1RPS6KA3
SCHEMBL15778019 0.78 MAPT (0.44) GPBAR1GAAMAOAMAOBPIM1
SCHEMBL29890929 0.78 MAPT (0.44) GPBAR1GAAMAOAMAOBPIM1
SCHEMBL29939399 0.78 ALDH1A1 (0.45) ALDH1A1GPBAR1PIM1NUDT1RPS6KA3
SCHEMBL4434876 0.77 GPBAR1 (0.43) ALDH1A1KDM4EGPBAR1HPGDSMN1; SMN2
SCHEMBL21647183 0.77 SMARCA2 (0.45) ALDH1A1KDM4EHPGDSMN1; SMN2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110545817-B GSK-3 inhibitors 百时美施贵宝公司 2022-11-15 CN disclosed
EP-3544613-B1 GSK-3 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-06-09 EP disclosed
US-10752609-B2 GSK-3 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-25 US disclosed
CN-110545817-A GSK-3 inhibitors SQUIBB BRISTOL MYERS COMPANY 2019-12-06 CN disclosed
US-20190315714-A1 GSK-3 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-10-17 US disclosed
EP-3544613-A1 GSK-3 INHIBITORS Bristol-Myers Squibb Company (US) 2019-10-02 EP disclosed
WO-2018098412-A1 GSK-3 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-31 WO disclosed
WO-2010115901-A1 PYRROLOPYRIDINE THERAPEUTIC COMPOUNDS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315714-A1 GSK-3 INHIBITORS GSK3B, GSK3A, GSKIP ALDH1A1 4374/4885KDM4E 2680/4885GPBAR1 515/4885
US-10752609-B2 GSK-3 inhibitors GSK3B, GSK3A, GSKIP ALDH1A1 4374/4885KDM4E 2680/4885GPBAR1 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.